PhaseBio Pharmaceuticals Stock (OTC: PHASQ)

Latest news for PhaseBio Pharmaceuticals (OTC:PHASQ) Stock

PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.

PHASEBIO PHARMA INC by PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals Inc

Telsey Advisory Group analyst Joseph Feldman maintains Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) with a Outperform and lowers the price target from $155 to $120.

News

Price Target

Analyst Ratings

FIVE

Telsey Advisory Group Maintains Outperform on Five Below, Lowers Price Target to $120

Whales with a lot of money to spend have taken a noticeably bearish stance on Charter Communications.
Looking at options history for Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 10% of the investors opened trades with bullish expectations and 70% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $197,400 and 4, calls, for a total amount of $244,150.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $230.0 to $400.0 for Charter Communications over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Charter Communications options trades today is 496.86 with a total volume of 138.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Charter Communications's big money trades within a strike price range of $230.0 to $400.0 over the last 30 days.
<h3>Charter Communications Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721241058_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$16.0</td>
<td>$15.1</td>
<td>$16.0</td>
<td>$400.00</td>
<td>$160.0K</td>
<td>2.7K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CHTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$5.3</td>
<td>$5.0</td>
<td>$5.2</td>
<td>$230.00</td>
<td>$43.1K</td>
<td>237</td>
<td style="text-align: right;">54</td>
</tr>
<tr>
<td>CHTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.3</td>
<td>$4.4</td>
<td>$5.2</td>
<td>$230.00</td>
<td>$37.4K</td>
<td>237</td>
<td style="text-align: right;">54</td>
</tr>
<tr>
<td>CHTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$31.6</td>
<td>$30.6</td>
<td>$31.6</td>
<td>$330.00</td>
<td>$34.7K</td>
<td>10</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$66.9</td>
<td>$63.0</td>
<td>$63.0</td>
<td>$350.00</td>
<td>$31.5K</td>
<td>94</td>
<td style="text-align: right;">3</td>
</tr>
</tbody>
</table>

<h3>About Charter Communications</h3>
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 57 million US homes and businesses, around 40% of the country. Across this footprint, Charter serves 30 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
After a thorough review of the options trading surrounding Charter Communications, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Charter Communications Standing Right Now?</h3>
<ul>
<li>With a volume of 765,007, the price of CHTR is up 0.97% at $330.58. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 9 days.</li>
</ul>
<h3>What The Experts Say On Charter Communications</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $252.5.
<ul>
<li>In a cautious move, an analyst from Goldman Sachs downgraded its rating to Sell, setting a price target of $250. </li>
<li>An analyst from Citigroup downgraded its action to Sell with a price target of $255. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Charter Communications with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

CHTR

Spotlight on Charter Communications: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Carnival.
Looking at options history for Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $333,649 and 9, calls, for a total amount of $287,330.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $17.0 to $35.0 for Carnival over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Carnival's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Carnival's significant trades, within a strike price range of $17.0 to $35.0, over the past month.
<h3>Carnival Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721241054_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.85</td>
<td>$8.75</td>
<td>$8.75</td>
<td>$27.00</td>
<td>$261.6K</td>
<td>312</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.02</td>
<td>$1.98</td>
<td>$1.99</td>
<td>$20.00</td>
<td>$47.3K</td>
<td>30.8K</td>
<td style="text-align: right;">548</td>
</tr>
<tr>
<td>CCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.25</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$21.00</td>
<td>$39.6K</td>
<td>273</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$1.73</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$17.00</td>
<td>$34.0K</td>
<td>24.0K</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>CCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/02/24</td>
<td>$0.16</td>
<td>$0.15</td>
<td>$0.16</td>
<td>$17.00</td>
<td>$32.3K</td>
<td>427</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About Carnival</h3>
Carnival is the largest global cruise company, with 92 ships in service at the end of fiscal 2023. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&amp;O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It's currently folding its P&amp;O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 13 million guests in 2019, prior to covid-19, a level it reached again in 2023.
<h3>Where Is Carnival Standing Right Now?</h3>
<ul>
<li>With a trading volume of 19,040,582, the price of CCL is down by -3.65%, reaching $18.48.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 72 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Carnival</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $22.4.
<ul>
<li>An analyst from Citigroup has decided to maintain their Buy rating on Carnival, which currently sits at a price target of $22. </li>
<li>Consistent in their evaluation, an analyst from Deutsche Bank keeps a Hold rating on Carnival with a target price of $19. </li>
<li>An analyst from B of A Securities has decided to maintain their Buy rating on Carnival, which currently sits at a price target of $24. </li>
<li>Consistent in their evaluation, an analyst from Argus Research keeps a Buy rating on Carnival with a target price of $25. </li>
<li>Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Carnival, targeting a price of $22. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Carnival options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Carnival's Options Frenzy: What You Need to Know

Whales with a lot of money to spend have taken a noticeably bullish stance on KLA.
Looking at options history for KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) we detected 29 trades.
If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations and 31% with bearish.
From the overall spotted trades, 18 are puts, for a total amount of $1,066,035 and 11, calls, for a total amount of $523,769.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $680.0 to $1140.0 for KLA over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for KLA's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across KLA's significant trades, within a strike price range of $680.0 to $1140.0, over the past month.
<h3>KLA 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721241049_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$33.6</td>
<td>$27.6</td>
<td>$33.7</td>
<td>$830.00</td>
<td>$250.7K</td>
<td style="text-align: right;">126</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$216.0</td>
<td>$210.0</td>
<td>$211.27</td>
<td>$700.00</td>
<td>$105.6K</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$36.6</td>
<td>$35.5</td>
<td>$35.5</td>
<td>$700.00</td>
<td>$71.0K</td>
<td style="text-align: right;">116</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$26.4</td>
<td>$21.0</td>
<td>$23.4</td>
<td>$900.00</td>
<td>$70.2K</td>
<td style="text-align: right;">199</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$75.0</td>
<td>$67.8</td>
<td>$70.15</td>
<td>$877.50</td>
<td>$70.1K</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About KLA</h3>
KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.
Following our analysis of the options activities associated with KLA, we pivot to a closer look at the company's own performance.
<h3>KLA's Current Market Status</h3>
<ul>
<li>Trading volume stands at 590,309, with KLAC's price down by -8.04%, positioned at $797.42.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 7 days.</li>
</ul>
<h3>Expert Opinions on KLA</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $935.0.
<ul>
<li>An analyst from Cantor Fitzgerald persists with their Neutral rating on KLA, maintaining a target price of $950. </li>
<li>Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on KLA with a target price of $875. </li>
<li>Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for KLA, targeting a price of $980. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest KLA options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

KLAC

Looking At KLA's Recent Unusual Options Activity

KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) has outperformed the market over the past 20 years by 7.85% on an annualized basis producing an average annual return of 16.37%. Currently, KLA has a market capitalization of $107.36 billion. 
Buying $100 In KLAC: If an investor had bought $100 of KLAC stock 20 years ago, it would be worth $2,057.33 today based on a price of $797.42 for KLAC at the time of writing.
<h3>KLA's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721241016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In KLA 20 Years Ago Would Be Worth This Much Today

Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) has outperformed the market over the past 5 years by 12.96% on an annualized basis producing an average annual return of 26.14%. Currently, Owens-Corning has a market capitalization of $15.31 billion. 
Buying $100 In OC: If an investor had bought $100 of OC stock 5 years ago, it would be worth $323.06 today based on a price of $176.65 for OC at the time of writing.
<h3>Owens-Corning's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721241011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Owens-Corning 5 Years Ago Would Be Worth Today

TD Cowen analyst Andrew Charles maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Hold and lowers the price target from $85 to $81.

SBUX

TD Cowen Maintains Hold on Starbucks, Lowers Price Target to $81

TD Cowen analyst Andrew Charles maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Buy and lowers the price target from $305 to $285.

TD Cowen Maintains Buy on McDonald's, Lowers Price Target to $285

V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) shares are trading higher Wednesday after the company announced it entered into an agreement to sell its Supreme brand to EssilorLuxottica <a href="https://www.benzinga.com/markets/equities/24/07/39819517/why-apparel-company-vf-corp-shares-are-surging-today">for $1.5 billion in cash.</a>
The Details:
VF said it expects the sale of Supreme to be dilutive to its earnings per share in VF's 2025 fiscal year. Supreme contributed $538 million of revenue and $166 million in operating income during VF's 2024 fiscal year.
"Under VF, Supreme expanded its presence in the key markets of China and South Korea and has returned to delivering strong growth. However, given the brand's distinct business model and VF's integrated model, our strategic portfolio review concluded there are limited synergies between Supreme and VF, making a sale a natural next step," Bracken Darrell, CEO at VF, said in a <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000103379/000119312524179856/d871255d8k.htm">press release</a>.&nbsp;
Read Next:<a href="https://www.benzinga.com/news/24/07/39796841/lucids-stock-drives-higher-on-2025-model-year-updates-whats-going-on"> Lucid&#8217;s Stock Drives Higher On 2025 Model Year Updates: What&#8217;s Going On?</a>
VF Corporation shares are moving higher on above-average trading volume as investors digest the sale of the Supreme brand. The stock is climbing above its 50-day moving average of $13.17. 
VF Corp is set to report its first-quarter 2025 results on Aug. 6 after the closing bell. According to estimates from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, analysts expect the company to report losses of 37 cents per share and quarterly revenue of $1.85 billion.&nbsp;
<h2 class="wp-block-heading">Should I Sell My VFC Stock? </h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
VFC shares have lost 24.17% year to date. This compares to the average annual return of -40.25%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. VF stock currently has an RSI of 70.57, indicating overbought conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
VFC Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, VF Corporation shares are up 13.6% at $16.16 at the time of publication Wednesday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39805320/what-happened-with-canopy-growth-stock-today">What Happened With Canopy Growth Stock Today?</a></li>
</ul>
Image: Shutterstock

Movers

What's Going On VF Corp Stock After Supreme Brand Sold For $1.5 Billion?

It&#8217;s deep red on Wall Street on Wednesday, with tech stocks sharply falling amid a semiconductor broad-based selloff following news that the Biden administration is hastening<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39821315/ai-earthquake-semiconductors-suffer-worst-selloff-in-years-on-stricter-us-chip-expo"> export restrictions to China. </a>
Bloomberg reported on Wednesday that the U.S. administration has advised its allies to impose the strictest trade restrictions possible if companies such as Tokyo Electron Ltd. (OTCPK: TOELY) and ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) persist in supplying advanced chips to China. Shares of the Dutch chipmaker ASML Holding fell nearly 12%, notching the worst decline since March 2020. 
The tech-heavy Nasdaq 100 tumbled by 2.7% at 12:45 p.m. ET, marking the worst session since late August 2023. The semiconductor industry was the hardest hit. The iShares Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>) and the VanEck Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>) both plummeted over 6%, marking their worst day since October 2022.
The elite group of the &#8216;Magnificent Seven,&#8217; tracked by the Roundhill Magnificent Seven ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>), saw a collective market cap loss of $500 billion in a single trading session. Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) alone plummeted 7%, accounting for a $180 billion loss.
The S&amp;P 500 dropped 1.2%, while blue-chip stocks of the Dow Jones rose 0.6% to 41,200 points, extending their all-time highs and marking a sixth consecutive session of gains. Meanwhile, small caps took a breather, with the Russell 2000 index falling 1%, ending a five-day winning streak.
U.S. natural gas futures fell over 6%, hitting two-month lows, due to lower-than-expected cooling demand amid milder weather forecasts for the next two weeks.
Oil prices rallied 1.9% after U.S. inventories declined again last week. Gold edged down 0.5% from the all-time highs reached on Tuesday. The dollar fell 0.4%, with the dollar-yen pair dropping 1.3%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) eased 1.2%. 
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In US Major Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,154.73</td>
<td>0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,240.18</td>
<td>-1.1%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,592.13</td>
<td>-1.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,862.83</td>
<td>-2.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:05 p.m. ET</figcaption></figure>
According to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071724&amp;t=be2bearmibe3na1">Benzinga Pro</a> data: 
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was 1.4% lower to $557.02.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose by 0.4% to $411.20.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust&nbsp;(ARCA:&nbsp;<a href="https://www.benzinga.com/quote/qqq" target="_blank" rel="noreferrer noopener"></a><a href="https://www.benzinga.com/quote/qqq" target="_blank" rel="noreferrer noopener"></a>QQQ) eased 2.7% to $482.82.</li>
<li>Sector-wise, the&nbsp;Consumer Staples Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)&nbsp;outperformed, up by 1.3%, while the&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 3.6%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul>
<li>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) tumbled 8.3%, dropping below the 50-day moving average support. </li>
<li>U.S.-listed shares of Taiwan Semiconductor Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) plummeted 7% following reports that U.S. presidential candidate Donald Trump suggested Taiwan should compensate the U.S. for its defense.</li>
<li>British chipmaker Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) tumbled 8.7%.</li>
<li>Other chip giants, including Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) and Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), also saw declined by about 8%.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) rallied 3.7% on stronger-than-expected quarterly results. </li>
<li>Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) plunged 9.4%, following a 10.2% drop on Tuesday, as several analysts lowered their price targets in response to disappointing Q2 earnings.</li>
<li>Other stocks reacting to company earnings were Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), down 6.5%, U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>), up 4.6%, Ally Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>), down 3%, Northern Trust Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>), down 7%, Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>), up 3.4% and Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>), up 0.6%. </li>
<li>Companies reporting after the close include Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>), Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>), Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>), SL Green Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>), Steel Dynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) and United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>).</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39819662/bank-of-america-analysts-stick-to-december-rate-cut-prediction-brace-for-election-f">Bank Of America Analysts Stick To December Rate Cut Prediction, Brace For Election-Fueled S&amp;P 500 Turbulence</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Sector ETFs

Commodities

Econ #s

Tech

ETFs

$BTC

ALLY

AMAT

ASML

SPDR Dow Jones Industrial Average ETF Trust

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

LRCX

MAGS

MRVL

NTRS

NVDA

SCHW

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

STLD

TOELY

Nasdaq 100 Suffers Worst Day In 11 Months As Chipmakers Tumble On China Curbs; Magnificent 7 Wipe Out $500B : What's Driving Markets Wednesday?

WIIM

ICHR

NTAP

PSTG

SMCI

VECO

Shares of hardware and data center companies are trading lower amid a selloff in chips and AI-related stocks.

The European Commission faced criticism from Europe&#8217;s second-highest court regarding transparency issues surrounding COVID-19 vaccine <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31170243/european-commission-keeps-mum-on-talks-regarding-pfizer-covid-19-vaccine-contract-report" rel="noreferrer noopener">contracts from four years ago</a>.
This scrutiny comes on the eve of a crucial vote on Commission head Ursula von der Leyen&#8216;s reelection bid.
Some European lawmakers have been vocal about their dissatisfaction with how the Commission handled its multibillion-euro contracts, particularly its failure to disclose text messages between von der Leyen and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla regarding one of the agreements.
In 2022, a&nbsp;Pfizer executive &#8220;categorically&#8221; ruled out that the pharma giant&#8217;s chief executive agreed on the European COVID-19 contract via <a target="_blank" href="https://www.benzinga.com/general/biotech/22/10/29203684/pfizers-executive-says-european-covid-19-vaccine-contract-negotiations-did-not-happen-over-text-m" rel="noreferrer noopener">mobile phone text messages</a>.
The Commission contends that these messages were not retained.
During the height of the pandemic, the Commission secured agreements with several major companies for COVID vaccine supplies, including AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), Pfizer, and Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39687792/emergent-biosolutions-and-johnson-johnson-resolve-claims-over-covid-19-vaccine-manufacturing" rel="noreferrer noopener">Emergent BioSolutions And Johnson &amp; Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing</a>.
In response to requests from some members of the European Parliament for full access to these documents, Reuters noted that the Commission provided only partial access, citing the need to protect commercial interests and the decision-making process through redactions.
&#8220;The Commission did not give the public sufficiently wide access to the purchase agreements for COVID-19 vaccines,&#8221; they said.
The General Court in Luxembourg upheld the lawmakers&#8217; challenge, although the Commission claimed partial success in defending certain contract clauses.
&#8220;In general, the Commission grants the widest possible public access to documents, in line with the principles of openness and transparency,&#8221; Reuters noted, citing the statement.
&#8220;In these cases, the Commission needed to strike a difficult balance between the right of the public, including MEPs (members of the European Parliament), to information, and the legal requirements emanating from the COVID-19 contracts themselves, which could result in claims for damages at the cost of taxpayers&#8217; money.&#8221;
Meanwhile, the European Parliament is scheduled to vote on Thursday regarding von der Leyen&#8217;s candidacy for a second term amid ongoing scrutiny and legal challenges concerning transparency issues.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39602190/london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents" target="_blank" rel="noreferrer noopener">London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents</a>.</li>
</ul>
Photo via Wikimedia Commons

Biotech

Eurozone

Health Care

Legal

General

BNTX

MRNA

European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment

Wednesday, 4D Molecular Therapeutics, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) unveiled interim 24-week data from the Population Extension cohort of its PRISM <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39810122/4dmt-announces-positive-phase-2-prism-interim-results-for-intravitreal-4d-150-in-a-broad-wet-amd-p" rel="noreferrer noopener">Phase 2 Clinical Trial</a>.
The trial evaluates intravitreal 4D-150 in a broad wet AMD patient population.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39211736/why-is-4d-molecular-therapeutics-stock-trading-lower-on-thursday-genetic-disease-focused-study-da" rel="noreferrer noopener">Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released</a>.
The findings were presented at the American Society of Retina Specialists Annual Scientific Meeting.
The Phase 2 PRISM Population Extension cohort evaluated 45 wet AMD patients previously treated with anti-VEGF injections, with 30 patients at 3E10 vg/eye (the planned Phase 3 dose) and 15 at 1E10 vg/eye (the low dose control).
In the expanded Phase 2 dataset, 4D-150 allowed 77% of 30 patients to become injection-free after 24 weeks, with 60% on low-dose arm.
An anti-VEGF treatment reduction was observed at the planned Phase 3 dose (3E10 vg/eye), with an 89% reduction in the mean annualized injection rate and 93% receiving 0 or 1 injection.
The data also showed improved visual acuity and retina anatomic outcomes.
The study reported no significant inflammation or 4D 150–related serious adverse events.
Long-term follow-up of Phase 1 patients treated with 4D-150 indicated stable visual acuity and retinal thickness over two years.
4D-150 demonstrated safety and efficacy in the PRISM (wet AMD) and SPECTRA (DME) clinical trials.
No significant inflammation or serious adverse events were reported among 139 dosed patients across both trials.
Upcoming milestones include the final Phase 3 trial design update in September 2024 and the initiation of the first Phase 3 trial in the first quarter of 2025.
Further analyses from the PRISM and SPECTRA studies are expected in early 2025.
Price Action: FDMT shares are down 35.7% at $17.19 at last check Wednesday. During the premarket session, shares reached as high as $29.1.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/03/37991496/4d-molecular-therapeutics-outlines-pivotal-development-plans-for-cystic-fibrosis-rare-inherited-d" target="_blank" rel="noreferrer noopener">4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease</a>.</li>
</ul>

FDMT

4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate

CFRA analyst Angelo Zino maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Buy and raises the price target from $240 to $260.

AAPL

CFRA Maintains Buy on Apple, Raises Price Target to $260

Cantor Fitzgerald analyst Brett Knoblauch initiated coverage on Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>), <a target="_blank" href="https://www.benzinga.com/quote/CORZ/analyst-ratings" rel="noreferrer noopener">with a price forecast of $20.</a>
According to the analyst, Bitcoin miners currently have one of the most coveted assets in the world &#8211; access to power.
In June 2024, Core Scientific announced a deal with CoreWeave (private), following which<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener"> shares went up meaningfully.</a>
With CoreWeave, Core Scientific was the first Bitcoin miner to sign a meaningful AI/HPC deal.
In what has now been extended, CoreWeave will lease 270 MW from Core Scientific for 12 years, and pay the company a total of $4.725 billion over that duration, amounting to ~$1.45 million per MW.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/07/39716492/block-and-core-scientific-enter-supply-agreement-for-mining-asics" rel="noreferrer noopener">Block and Core Scientific Enter Supply Agreement for Mining ASICs</a>
What is most differentiated about this deal that other miners will not be able to replicate is the fact that CoreWeave will fund the entire capex buildout itself (~$1.3 billion).
Per the analyst, this is effectively an interest-free loan for CoreWeave, which can use the annuity like revenue stream to fund additional capacity expansion, and to potentially lever up the business to maximize equity returns.
Core Scientific has earmarked an additional 322 MW for AI/HPC, which could generate an additional $335 million in <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">annual revenue and $268 million in annual profits.</a>
Long term – the analyst sees the potential for shares to be multiples higher than the current price target.
Price Action: CORZ shares are trading lower by 5.17% to $11.10 at last check Wednesday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39749573/nio-advances-vehicle-safety-with-ai-enhanced-automatic-emergency-braking-and-navigation-features" target="_blank" rel="noreferrer noopener">NIO Advances Vehicle Safety With AI-Enhanced Automatic Emergency Braking And Navigation Features In Latest Update</a></li>
</ul>

Analyst Color

Initiation

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific Analyst Emphasizes 'Access To Power' In Bitcoin Mining Assets - Deal With CoreWeave Under Focus

Cassava Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock is trading lower on Wednesday on a heavy session volume of 14.35 million, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
The Board of Directors appointed Richard (Rick) Barry as Executive Chairman and the company&#8217;s principal executive officer, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39813058/cassava-sciences-announces-changes-in-executive-leadership-enhanced-corporate-governance-and-other" rel="noreferrer noopener">effective immediately</a>. The company is searching for a new permanent CEO.
Mr. Barry succeeds Remi Barbier, the Company&#8217;s Chairman, President, and CEO, who resigned and will remain employed by the Company until September 13, 2024, in a non-executive capacity, without duties or responsibilities.
Lindsay Burns, SVP of Neuroscience at Cassava, is also leaving the company. Cassava and Dr. Burns have agreed that she step down from her role with the company, effective immediately.
Following her separation from the company and for a one-year period, Dr. Burns will furnish consulting services as and to the extent reasonably requested by Cassava to provide information and support for scientific research and/or obtain governmental approval for the company&#8217;s products.
Cassava may, at its sole discretion, extend the term of the consulting agreement by up to an additional year.
Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39578081/cassava-sciences-cooperates-with-doj-sec-on-controversial-alzheimers-drug-investigation" rel="noreferrer noopener">Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer&#8217;s Drug Investigation</a>.
Mr. Barry said. &#8220;While our priority remains the development of a potentially effective treatment for Alzheimer&#8217;s disease, the Board has a steadfast commitment to doing so with transparency, accountability, and highest ethical business practices.&#8221; Among the actions the company is taking are:
<ul>
<li>New Leadership: The Board plans to separate the Chairman and CEO roles after identifying a new CEO.</li>
<li>Single-minded Commitment to Scientific Rigor and Honest Transparency: The company&#8217;s mission is to evaluate simufilam as a groundbreaking Alzheimer&#8217;s treatment, focusing on scientific rigor and transparency with patients, government agencies, and investors. All study results will be promptly and accurately posted on <a href="https://www.globenewswire.com/Tracker?data=vZZ6OkMSOaios8h0rajvwWFmEyTvQ8IToK5KGykCu4U97tT9zTPV9sYfj4rz1dS4u4NUT6tyetMZxzwISZ444PosvJOTncWJZySdB_IktB8=" target="_blank" rel="noreferrer noopener">clinicaltrials.gov</a>.</li>
<li>Rigorous Clinical Trials:  The ongoing Phase 3 trials adhere to FDA and industry standards to ensure the integrity of results. Under the FDA-reviewed protocols, no company personnel know or will know which subjects receive the drug or placebo.</li>
<li>Blinding information is maintained by a small group at CRO, Premier Research. Additionally, company personnel do not have access to sub-study results or other data that could reveal which patients are on placebo.</li>
<li>All data is sent directly to Premier Research. Statistical analyses are conducted by professional biostatisticians at Pentara Corporation, with trial results transmitted to them independently by the CRO, without company involvement.</li>
<li>Transparency in Communications and Reporting: Cassava is dedicated to maintaining transparent communication with its stakeholders. The company will resume quarterly analyst calls and ensure management is accessible to journalists. Cassava is also reviewing its disclosure practices to provide clear, comprehensive information. Ongoing dialogues with shareholders, employees, customers, regulators, and the community will shape the company&#8217;s governance practices.</li>
</ul>
Price Action: SAVA shares are down 27.20% at $9.85 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/03/37605163/alzheimers-drug-trial-results-questioned-after-damning-fda-inspection-report" target="_blank" rel="noreferrer noopener">Alzheimer&#8217;s Drug Trial Results Questioned After &#8216;Damning&#8217; FDA Inspection Report</a>.</li>
</ul>

Management

SAVA

Cassava Sciences Faces Leadership Shake-Up, Prioritizes Transparency And Scientific Rigor In Alzheimer's Trials

Chewy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) short percent of float has risen 9.25% since its last report. The company recently reported that it has 21.75 million shares sold short, which is 18.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Chewy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721240120_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chewy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Chewy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Chewy's peer group average for short interest as a percentage of float is 12.94%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

CHWY

Peering Into Chewy's Recent Short Interest

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has fallen 6.57% since its last report. The company recently reported that it has 7.61 million shares sold short, which is 2.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721240115_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 6.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(VTR) - Analyzing Ventas's Short Interest

Avery Dennison's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) short percent of float has risen 3.23% since its last report. The company recently reported that it has 1.58 million shares sold short, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Avery Dennison Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721240110_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Avery Dennison has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Avery Dennison's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Avery Dennison's peer group average for short interest as a percentage of float is 4.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Avery Dennison's Recent Short Interest

Bernstein analyst Alexia Howard maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Outperform and lowers the price target from $90 to $88.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

PhaseBio Pharmaceuticals

News

Latest news for PhaseBio Pharmaceuticals (OTC:PHASQ) Stock